(AJMC.org) BEING DIAGNOSED WITH CANCER is often the scariest news a patient will hear in his or her lifetime. In addition to the physical toll of the disease itself, there are numerous other factors associated ...
(OncLive) Immuno-oncology (I/O) drugs have the potential to improve the level of care in many respects, but they bring with them a host of problems related to implementation that require a completely new ...
(ASCO Post) Lee S. Schwartzberg, MD, of The West Clinic, reports on progress of the now year-old ACCC initiative to speed adoption of immunotherapeutics in community practices from the 2016 ASCO Annual ...
(BMS) Mar 30, 2017 - Bristol-Myers Squibb Company and Foundation Medicine today announced a collaboration that leverages Foundation Medicine’s comprehensive genomic profiling and molecular information solutions to identify predictive biomarkers such as Tumor Mutational Burden (TMB) and Microsatellite Instability (MSI) in patients enroll...
(Immunovaccine) Mar 29, 2017 - Immunovaccine Inc., a clinical stage vaccine and immunotherapy company, today announced the first interim data analysis from its ongoing Phase 1b clinical study of its novel T-cell activating immuno-oncology candidate, DPX-Survivac, in combination with epacadostat and low-dose cyclophosphamide.
(Philadelphia Inquirer/HealthDay News) Mar 29, 2017 - The cancer-preventing HPV vaccine does not appear to have any ill effect on babies unintentionally exposed to it in the womb, researchers report.
(Yahoo! Finance) Mar 29, 2017 - Amgen today announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review the supplemental Biologics License Application (sBLA) for BLINCYTO® (blinatumomab) to include overall survival (OS) data from the Phase 3 TOWER study.
(Novartis) Mar 29, 2017 - Novartis announced today that the US Food and Drug Administration (FDA) has accepted the company's Biologics License Application (BLA) filing and granted priority review for CTL019 (tisagenlecleucel-T), an investigational chimeric antigen receptor T cell (CAR-T) therapy, in relapsed and refractory (r/r) pediatric...
(Endpoints News) Mar 28, 2017 - Bristol-Myers Squibb is teaming up with the growing virtual network of scientists at the Parker Institute for Cancer Immunotherapy to expand its focus on an already thick pipeline of immuno-oncology programs.
(Penn Medicine) Mar 29, 2017 - A series of studies from the Perelman School of Medicine at the University of Pennsylvania demonstrate the promise of new diagnostic methods. Three of the studies focus on liquid biopsies, an innovation which uses blood tests instead of surgical procedures in hopes of detecting cancer.
Checkpoint Inhibitors: Common Immune-Related Adverse Events and Their Management .
Clin J Oncol Nurs. 2017 Apr 01;21(2):45-52
Authors: Gordon R, Kasler MK, Stasi K, Shames Y, Errante M, Ciccolini K, Skripnik Lucas A, Raasch P, Fischer-Cartlidge E
Cancer Immunotherapy: An Evidence-Based Overview and Implications for Practice.
Clin J Oncol Nurs. 2017 Apr 01;21(2):13-21
Authors: Bayer V, Amaya B, Baniewicz D, Callahan C, Marsh L, McCoy AS
BACKGROUND: Significant research progress has been made in immunothe...
Molecular Pathways: Oncologic Pathways and Their Role in T-cell Exclusion and Immune Evasion- A New Role for the AXL Receptor Tyrosine Kinase.
Clin Cancer Res. 2017 Mar 13;:
Authors: Aguilera TA, Giaccia AJ
With the clinical impact of CTLA-4 and PD-1/PD-L1 immu...
Characterization of the anti-PD-1 antibody REGN2810 and its antitumor activity in human PD-1 knock-in mice.
Mol Cancer Ther. 2017 Mar 06;:
Authors: Burova E, Hermann A, Waite J, Potocky T, Lai V, Hong S, Liu M, Allbritton O, Woodruff A, Wu Q, D'Orvilliers A, Garnova E, Rafique A, Pouey...
Interplay between Immune Checkpoint Proteins and Cellular Metabolism.
Cancer Res. 2017 Feb 28;:
Authors: Lim S, Phillips JB, Madeira da Silva L, Zhou M, Fodstad O, Owen LB, Tan M
With the recent successes in immuno-oncology, renewed interest in the role of immu...
Heterogeneity in immune marker expression after acquisition of resistance to EGFR kinase inhibitors: analysis of a case with small cell lung cancer transformation.
J Thorac Oncol. 2017 Feb 10;:
Authors: Suda K, Murakami I, Yu H, Kim J, Ellison K, Rivard CJ, Mitsudomi T, Hirsch FR
Differential PI3Kδ signaling in CD4+ T cell subsets enables selective targeting of T regulatory cells to enhance cancer immunotherapy.
Cancer Res. 2017 Jan 20;:
Authors: Ahmad S, Abu-Eid R, Shrimali RK, Webb M, Verma V, Doroodchi A, Berrong Z, Samara RN, Rodriguez PC, Mkrtichyan M, Kh...
An immunogram for the cancer-immunity cycle: towards personalized immunotherapy of lung cancer.
J Thorac Oncol. 2017 Jan 11;:
Authors: Karasaki T, Nagayama K, Kuwano H, Nitadori JI, Sato M, Anraku M, Hosoi A, Matsushita H, Morishita Y, Kashiwabara K, Takazawa M, Ohara O, Kakimi K, Nak...
A novel murine GITR ligand fusion protein induces antitumor activity as a monotherapy, which is further enhanced in combination with an OX40 agonist.
Clin Cancer Res. 2017 Jan 09;:
Authors: Leyland R, Watkins A, Mulgrew K, Holoweckyj N, Bamber L, Tigue NJ, Offer E, Andrews J, Yan L, Mu...
EN2: A candidate antigen for the development of targeted therapies in ovarian cancer.
J Clin Oncol. 2011 May 20;29(15_suppl):e15528
Authors: Michael A, Riley C, Bokaee S, Denyer M, Pandha HS, Annels NE
e15528 Background: Ovarian cancer remains the most lethal g...
MAGRIT phase III trial: MAGE-A3 antigen-specific cancer immunotherapy (ASCI) as adjuvant therapy in patients with completely resected stage IB-IIIA NSCLC.
J Clin Oncol. 2011 May 20;29(15_suppl):TPS210
Authors: Therasse P, Vansteenkiste JF, Zielinski M, De Pas TM, Atanackovic D, Sequist...